News | March 01, 2025
Biocon launches GLP -1, Liraglutide, in UK
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
The PIPE offering consists of 36,190,476 units
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score
Standalone profit from operations for Q4-2024 were Rs. 108 crore
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
USFDA inspection at Emcure Pharmaceuticals API facility
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Subscribe To Our Newsletter & Stay Updated
